Not necessarily. A 5% formula contains more of the Volufiline trade ingredient than a comparable 3% formula, but that does not mean it will produce proportionally better visible results. Product format, supporting ingredients, formulation stability, sensory performance and finished-product testing all matter. There is also no strong independent facial study directly comparing 3% and 5% Volufiline.
If you have been shopping for Volufiline skincare—or researching the ingredient for a new product—you have probably noticed that brands like to put the percentage front and center. One serum contains 3% Volufiline, another advertises 5%, and some newer products go much higher. It is easy to look at those numbers and assume that the bigger percentage must mean the stronger or more effective product.
I wouldn’t even compare them.
I like seeing a percentage for Volufiline in a formula but it tells me far less than what I see on many product pages. I want to know what the percentage means, what formula it is used in, what ingredients it is mixed with, what the finished product feels and performs like and whether the claims being made are supported by evidence.
This is particularly the case when you compare 3% and 5%. Historically, the 5% level is somewhat justified, as it is seen in supplier recommendations, and the most famous human testing involving Volufiline. But there’s no evidence that a 5% facial product is going to be better than a 3% product – either consistently or proportionately.
Thus the useful question is not, “Which percentage is higher?“But what does that percentage mean in the final product?”
But before we go into the 3% vs 5% comparison, there is one key point that tends to get lost in internet discussions: Volufiline is a commercial cosmetic ingredient, not simply another name for pure sarsasapogenin.
Volufiline is a cosmetic ingredient manufactured by Sederma (a member of Croda) and marketed as an oil-based ingredient containing Anemarrhena asphodeloides root extract in hydrogenated polyisobutene. Sarsasapogenin is the botanical extract and the heart of the ingredient story, but a bottle labelled “5% Volufiline” should not be taken to be 5% pure sarsasapogenin.
The difference is greater than it sounds.
In an existing serum containing 3% Volufiline the percentage is usually the amount of the supplied Volufiline trade ingredient that has been used in the formulation. The same applies for a 5% formula. What consumers are doing is just comparing the quantity of a formulated cosmetic ingredient, not of an isolated molecule.
This is one reason I get skittish when I see concentration numbers being used almost like pharmaceutical strength indicators. Cosmetic formulations are rarely that simple, and Volufiline is a good example of why.
But once you’ve compared enough Volufiline products, 5% starts to feel like an unofficial industry standard. There’s a reason for that. Historical technical material from Sederma suggested the use of Volufiline at around 5%. The human study most commonly cited in discussions of the ingredient also tested a formulation containing 5% Volufiline.
5% more background than some random marketing number, but I'd still be careful what we take from it.
The much discussed supplier study was small and looked at application to the breast area over a period of several weeks. It wasn’t a side by side facial study comparing 3% and 5% formulas on the cheeks, temples, lips or under eye area – the places where Volufiline is now most commonly discussed online.
So when I look at the historical 5% study to prove that a 5% facial serum must be more effective than a 3% serum, I see the evidence stretched farther than it should be.
It is reasonable to say that 5% is a historically relevant use level. Much less is there any basis to say that 5% is clinically proven to be the optimum concentration for every type of facial product.
Yes, in the strictest sense: if two formulas are otherwise similar, then the 5% version has more of the Volufiline trade ingredient than the 3% version.
But that still doesn’t answer the question most consumers are really asking when they ask which one is stronger.
What they really want to know is whether the 5% product provides visible better results. Currently, there are no independent human studies that convincingly compare 3% and 5% Volufiline facial formulations and demonstrate a clear dose-response relationship.
That means we can’t responsibly reduce the difference to mere arithmetic.
A 5% formula has about 67% more Volufiline ingredient than a 3% formula, but that does not mean it should produce 67% more visible plumping. Cosmetic ingredients don’t really follow a linear “more ingredient = proportionally more result” equation, especially when the finished formulation changes as the concentration increases.
Here is where marketing logic and formulation logic often begin to diverge. Marketing loves a big number. Formulation seldom does.
The scientific explanation for Volufiline is interesting, but I think it’s important to differentiate between different types of evidence, and not just treat everything as if it weighs the same.
The ingredient is based on sarsasapogenin from Anemarrhena asphodeloides. In the first place, Volufiline was associated with a "plumping" or fuller-looking skin story because supplier research has looked at mechanisms involving adipocyte differentiation and lipid storage.
Laboratory research can be useful for explaining why an ingredient is worth investigating, but cells in a laboratory are not the same as an ingredient moving through intact human facial skin and producing a visible cosmetic effect. That distinction is particularly important with Volufiline because many online claims jump very quickly from a proposed biological mechanism to statements such as “it grows facial fat.”
The human testing by the original supplier is a further level of evidence as it was done with an actual finished formulation used by people. That said, it still offers a narrow foundation for sweeping claims about facial volume. The study was relatively small, supplier-led and concentrated on a different anatomical area to the face.
What is lacking is solid, independent clinical evidence that topical Volufiline reliably increases facial adipose volume in humans.
But that does not mean Volufiline has no value as a cosmetic ingredient. It means I would describe the evidence more carefully: there is an interesting mechanism, historical supplier research and a recognizable cosmetic positioning around plumping, but the science is not strong enough to treat Volufiline as the topical equivalent of an injectable filler.
And that is where the conversation becomes a lot more interesting from a product-development perspective.
Volufiline is delivered in an oil-based system, so when you go from 3% to 5% it’s not just a matter of adding two more percentage points of the active and leaving everything else the same. You've got to fit that extra oil-phase stuff into the rest of the formulation.
That can be relatively easy, because the formula already has a meaningful oil phase, in a richer facial cream. The same concentration can require a lot more tweaking in a serum that’s supposed to feel light, absorb easily and layer under moisturiser.
A shift in the level of one oil-soluble ingredient can make a formulator rethink viscosity, emulsification, slip, absorption and after-feel.
I would hesitate to compare Volufiline products based on the number on the front of the package alone. Technically, a higher concentration does not do much good if the product becomes so heavy, greasy or unpleasant that customers stop using it on a regular basis.
At the formulation level, sensory performance is not an afterthought. It is part of the whether the product actually works as a consumer product.
This is an area where I think many brands unnecessarily err.
If a competitor comes out with a 5% Volufiline serum, you might feel like you need your product to be 5% or more to look competitive. This approach makes formulation a concentration race, and concentration races don’t always produce better products.
A 3% Volufiline serum can make perfect sense when Volufiline is only one part of a broader active system.
For example, I might view a concept based on 3% Volufiline + a multi-peptide complex very differently from a product based on 5% Volufiline as the single hero ingredient.
The first product isn’t competing on “We have more Volufiline.” Its story could be about plumping, firmness, smoother-looking skin and overall skin quality, with each ingredient doing a different job in that story.
This is especially useful in serums when brands want multiple well-known actives to work well together without an unnecessarily heavy texture.
It also makes the product a better story than just increasing the number on the front label.
Volufiline and peptides work well together from a product-concept perspective, as they provide a brand with the ability to speak to two related, but not the same, cosmetic concerns.
Volufiline is typically positioned around plumping and fuller-looking skin, while peptides are more commonly associated with firming, smoother-looking skin and support for an anti-aging formulation story.
That allows a product developer more freedom to develop a concept like:
Plumpness + Firmness + Smoother Skin
instead of putting all the claims on Volufiline.
From my perspective, that is a more credible way to develop a modern Volufiline serum. Rather than asking whether I can push the concentration from 3% to 5%, I would ask whether the entire active system makes sense for the product we are trying to create.
A 3% Volufiline peptide serum, for example, may be designed around a light texture, daily use and multi-active positioning. A 5% Volufiline cream may be richer and more ingredient-led. Both can make sense because they are doing different jobs.
There are still cases where I would go for 5% especially when Volufiline itself is supposed to be the main reason the customer notices the product.
A good example is a facial cream based on Volufiline. Creams often provide formulators with more latitude in the oil phase, and the richer texture can naturally lend itself to a plumping and moisturising position. Given the commercial story, the historical guidance we've seen from suppliers, 5% could be good for that kind of project.
The same goes for a targeted Volufiline eye cream or treatment serum, particularly if the brand wants to display the concentration on the packaging.
I would, however, still distinguish between marketing clarity and scientific superiority.
It's a very simple statement for a consumer to understand, “5% Volufiline” This does not imply the final product is better than all the others that use less.
This is important because product developers sometimes select concentrations for two very different reasons: one technical, one commercial. Both are legitimate concerns but we need to be clear which one is driving the decision.
When a brand comes to me and asks me should I use 3% or 5% Volufiline, one of the first questions I would ask is: What are we actually trying to make?
While Volufiline can be used in a serum, a facial cream and an eye cream, they should not necessarily follow the same formulation strategy.
Generally a serum should be light enough to layer with other skincare. That may drive the development toward a more balanced active system where Volufiline is combined with peptides, humectants or other ingredients rather than being the dominant ingredient in the whole formula.
In a facial cream, emollients have more room to spread and the sensory profile is richer, so you can add more of the oil phase.
An eye cream comes with another set of considerations: spreadability, migration, comfort around the eye area and packaging compatibility.
This is why I like to allow the product format to dictate the concentration rather than selecting a percentage first and then trying to make the formula fit around it.
If it were me comparing 2 Volufiline products for myself, I’d notice the concentration, but I wouldn’t stop there.
I’d consider how the brand describes the ingredient, what else is in the formulation, if the claims seem proportionate to the evidence, and if the product format makes sense for how I plan to use it.
I would also watch out for claims that are too aggressive.
Claims such as "grows facial fat," "replaces filler" or "permanently restores lost facial volume" go much further than the current evidence supports. So what if the supplier research is presented as if it proves an identical result in every finished facial product?
More defensible cosmetic language would be to address the appearance of the skin: plumper-looking, fuller-looking, firmer-looking or smoother-looking.
That distinction isn’t just scientific caution. It is also important from a regulatory point of view, particularly in markets such as the United States and the European Union, where cosmetic claims must remain appropriate for cosmetic products and substantiated.
I'd rather be able to defend a somewhat more conservative claim for a brand than make an aggressive claim that could cause regulatory or credibility problems down the line.
If a client asks me this question I would not answer it by saying 3% for entry level products and 5% for premium products. That kind of classification is useful, but it’s not how I would actually build the formula.
First I would look at the product positioning. If Volufiline is the star ingredient and the whole marketing concept is built around it, 5% may be the more logical starting point. If the goal is a multi-active serum where Volufiline is used in conjunction with peptides, humectants or barrier-support ingredients, 3% can be a perfectly reasonable direction to take.
Then I would look at the texture the brand wants, the packaging they are going to use, the target market, the supporting actives and the type of claims they want to make. I won't make the final decision on the level of Volufiline until after those decisions.
It’s not as exciting as just saying “more is better” but usually leads to a better product brief.
From a product-development perspective, there are three Volufiline concepts that make particularly good sense to me.
| Product Concept | Volufiline Direction | Product Story |
|---|---|---|
| Volufiline + Peptide Firming Serum | Around 3% | Lightweight multi-active plumping + firming |
| Volufiline Plumping Cream | Around 5% | Richer Volufiline-led plumping and moisturizing concept |
| Volufiline Peptide Eye Cream | 3–5% depending on formula | Smoother-, firmer- and plumper-looking eye area |
The point is not that every brand needs to use these exact concentrations . The point is that the percentage should match the product concept.
A 3% peptide serum is intentionally formulated differently from a 5% facial cream. Just because one has a higher number, they do not have to compete with one another.
If the question is merely which formula contains more Volufiline, the answer is simple: 5% is more than 3%.
But the question of which finished skin-care product is better gets a lot more complicated.
The benefit of the 5% concentration is that it is in line with the historical guidance of the supplier and the concentration used in the best known supplier human study. 3% can still be a viable option in a well designed multi-active formula, especially when Volufiline is combined with peptides or other complimentary actives.
What the data do not provide right now is a reliable rule that moving from 3% to 5% will provide a predictable increase in facial plumping.
That’s why I would assess the formulation as a whole before I’d assess the number on the package.
For me the order is more like this:
product concept → product format → actives to support → stability and skin feel → evidence → concentration.
The concentration is important, but should be one decision in a larger formulation strategy.
As consumers are increasingly aware of the ingredient by name, volufiline is commercially interesting. That creates an opportunity for brands, but it does create pressure to compete on concentration.”
I don't think the smartest answer is always to just put a bigger number on the bottle.
A well formulated 3% Volufiline + peptide serum can have a better formulation story than a poorly balanced product with just 5%. But then again, a well-thought-out 5% Volufiline cream makes perfect sense when the ingredient is deliberately positioned as the hero of the formula.
So, the better question for a skincare brand is not “How high can we make the percentage?”
It is “What Volufiline formula makes the most sense for the product we want consumers to use?”
That is the question I would answer before moving into samples, stability work or packaging development.
At Xiran Skincare, we can develop Volufiline serums, eye creams and facial creams with different active systems, including Volufiline + peptide concepts. Rather than treating concentration as the only selling point, we can adjust the formula, texture, supporting ingredients and packaging around the product positioning a brand actually wants to build.
There is no well-established independent facial study proving that 3% is either the minimum effective level or an insufficient level. A 3% concentration can make sense in a multi-active formula, particularly when Volufiline is combined with peptides or other complementary ingredients.
It contains more of the Volufiline trade ingredient, but that does not prove that it will deliver proportionally better visible facial results. There is currently no strong head-to-head human facial study comparing 3% and 5% Volufiline.
Five percent has historical relevance because it appears in supplier-recommended use information and in the best-known human testing associated with the ingredient. That makes it a familiar formulation and marketing level, although it should not be interpreted as the only effective concentration.
Yes. From a product-development perspective, the combination makes sense because Volufiline can support a plumping positioning while peptides contribute to a broader firming and smoother-looking skin story. The actual peptide system still needs to be selected according to the formula structure and stability requirements.
If Volufiline is intended to be the hero ingredient, 5% can be a logical starting point because of its historical supplier use level. If the goal is a multi-active serum combining Volufiline with peptides or other actives, 3% may make just as much sense. The final level should be confirmed through formulation and stability work rather than selected from marketing alone.
